The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean … Read more
It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools are too capable, and the commercial advantage too significant, for them not to become a sizeable part of our work and personal lives. But the … Read more
By Stephanie Anderson, Chief of Staff Representation in clinical trials is crucial for equitable healthcare. Yet, the nature of clinical trial sites, which have historically been based in municipal centers where patient populations are highest, automatically excludes huge swathes of the population, such as those living in rural areas. These sites are also rarely positioned … Read more
At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights … Read more
When Velocity Clinical Research launched in December 2017, it had just two sites. Owned sites (SMOs) were the prevalent model at the time, and site networks were a collection of independent sites with a single point of contact. Velocity offered an alternative – a wholly owned and fully integrated network of clinical trial sites. That … Read more
Paul Evans was featured in Applied Clinical Trials‘ latest article weighing in on the real-world implications of recent executive orders affecting DEI initiatives nationwide. In the piece, Paul underscores Velocity’s unwavering commitment to inclusive, patient-centered research environments, stating: “Velocity believes that clinical trials should be a safe space for the entire LGBT community… It’s important … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of a new article reporting on a study that found prolonged elevation of hepatic biomarkers and fibrosis (scarring) scores is associated with a greater risk of negative clinical outcomes in patients with primary biliary cholangitis (PBC). PBC is a rare liver disease that can … Read more
Velocity is collaborating with Merck to enhance the way trial insights are shared within Merck and across Velocity sites worldwide. Through fast-response data exchange, we’ve developed the Velocity Insight Platform (VIP), a dynamic dashboard that provides actionable metrics to optimize site activities. A huge thank you to the data team at Merck for their dedication … Read more
Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical care. In addition to her impact on the broader research community, … Read more
Clinical trials have been steadily leaving the UK for years. In 2021, just 2.2% of patients recruited to global trials were from the UK. By contrast, France, which has a similar population size, accounted for 3.9% that year. That’s not to say we don’t still have some clout (the UK ranks fourth globally for Phase … Read more